Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MAT2A | P31153 | 1/20 | 0.38 |
| ▸ | TACR3 | P29371 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3555919 | 0.92 | KDM4E (0.45) | KDM4EGAAMAPK1ALDH1A1SMN1; SMN2 | |
| SCHEMBL6821037 | 0.90 | ABCB1 (0.43) | KDM4EGAAMAPK1ALDH1A1SMN1; SMN2 | |
| SCHEMBL3565673 | 0.87 | ALDH1A1 (0.45) | KDM4EALDH1A1SMN1; SMN2SIGMAR1MEN1 | |
| SCHEMBL3560116 | 0.83 | KDM4E (0.43) | KDM4EGAAMAPK1ALDH1A1SMN1; SMN2 | |
| SCHEMBL3556742 | 0.83 | KDM4E (0.43) | KDM4EGAAMAPK1ALDH1A1SMN1; SMN2 | |
| SCHEMBL14953594 | 0.81 | KDM4E (0.41) | KDM4EGAAMAPK1ALDH1A1SMN1; SMN2 | |
| SCHEMBL6919614 | 0.81 | PTGS2 (0.46) | KDM4EGAAMAPK1ALDH1A1SMN1; SMN2 | |
| SCHEMBL14953558 | 0.81 | HTR6 (0.46) | KDM4ESIGMAR1HTR6MAT2A | |
| SCHEMBL3561464 | 0.81 | ALDH1A1 (0.45) | KDM4EALDH1A1SMN1; SMN2SIGMAR1MEN1 | |
| SCHEMBL6817304 | 0.81 | ESR1 (0.43) | KDM4EHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1567492-B1 | N-ARYLSULFONYL-3-AMINOALKOXYINDOLES | SUVEN LIFE SCIENCES LTD (IN) | 2013-05-22 | — | — | EP | disclosed |
| US-7718690-B2 | N-arylsulfonyl-3-aminoalkoxyindoles | RAMAKRISHNA VENKATA SATYA NIROGI | 2010-05-18 | — | — | US | disclosed |
| US-20090131507-A1 | N-arylsulfonyl-3-aminoalkoxyindoles | SUVEN LIFE SCIENCES LIMITED (IN) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131507-A1 | N-arylsulfonyl-3-aminoalkoxyindoles | HTR3C, HTR3A, AANAT | KDM4E 3751/4885GAA 4482/4885MAPK1 2581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.